Nuria Ajenjo - Concepedia

Author

Nuria Ajenjo

Spanish National Cancer Research Centre ORCID

Also Known As

Angel Perez-Nuñez, Angel Pérez-Núñez, Cecilia Sobrino, N Ajenjo, N. Ajenjo, Nuria Ajenjo

Publications

906

Citations

H-Index

Concepts

All Affiliations

Spanish National Cancer Research Centre Universidad de Cantabria Centro de Investigaciones Biológicas Margarita Salas Consejo Superior de Investigaciones Científicas

About

Nuria Ajenjo is an author at Spanish National Cancer Research Centre specializing in medicine, cell biology, and signal transduction.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	629
2	Cell Biology	4	4	515
3	Health Sciences	1	1	31
4	Natural Sciences	1	1	27
5	Cellular Physiology	1	1	27

Nuria Ajenjo

Publications

787

Citations

H-Index

Page 1

	Year	Citations
p38α MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis Ignacio Dolado, Aneta Swat, Nuria Ajenjo, Cancer Cell Redox SignalingCancer ResearchSignal TransductionReactive Oxygen SpeciesCell Signaling	2007	395
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition Carmen Blanco‐Aparicio, Ana Collazo, Julen Oyarzábal, Cancer Letters Signal TransductionSignaling PathwayCell RegulationReceptor Tyrosine KinaseApoptosis	2010	62
Subcellular Localization Determines the Protective Effects of Activated ERK2 against Distinct Apoptogenic Stimuli in Myeloid Leukemia Cells Nuria Ajenjo, Estela Cañón, Isabel Sánchez‐Pérez, Journal of Biological Chemistry	2004	57
The Rho Family GTPase Cdc42 Regulates the Activation of Ras/MAP Kinase by the Exchange Factor Ras-GRF Imanol Arozarena, David S. Aaronson, David Matallanas, Journal of Biological Chemistry	2000	46
Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors Joaquı́n Pastor, Julen Oyarzábal, Gustavo Saluste, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineRational Drug DesignPim Kinase InhibitorsPharmacological Agent	2012	44
Myc Antagonizes Ras-mediated Growth Arrest in Leukemia Cells through the Inhibition of the Ras-ERK-p21Cip1 Pathway José P. Vaqué, Joaquin Navascues, Yuzuru Shiio, Journal of Biological Chemistry	2004	43
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors Sonia Martı́nez, Sonsoles Rodríguez-Arístegui, Cristina Gómez de la Oliva, European Journal of Medicinal Chemistry Medicinal ChemistryPim InhibitorsMedicinePharmacological AgentPharmacotherapy	2019	37
A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis Lucía Zhu, Diana Retana, Pedro García‐Gómez, EMBO Molecular Medicine Neuro-oncologyDrug RepositioningClinical TranslationMedicineClinical Trials	2022	33
Myeloid Leukemia Cell Growth and Differentiation Are Independent of Mitogen-activated Protein Kinase ERK1/2 Activation Nuria Ajenjo, David S. Aaronson, Eva Ceballos, Journal of Biological Chemistry Mixed-phenotype Acute LeukemiaCell ProliferationTumor BiologyMyeloid NeoplasiaHematological Malignancy	2000	31
Regulation of c-Myc and Max in megakaryocytic and monocytic-macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c-Myc is down-regulated but does not inhibit differentiation. Ana Lerga, Piero Crespo, Marı́a T. Berciano, PubMed ImmunologyC-myc GeneCell ProliferationDifferentiation PathwaysCellular Physiology	1999	27

Page 1